The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents
Abstract
The ability of TNP‐470, a synthetic analog of fumagillin which has been described as an anti‐angiogenic agent, to potentiate cytotoxic cancer therapies was investigated in vivo in the murine FSaIIC fibrosarcoma and the Lewis lung carcinoma. TNP‐470 was more toxic toward FSaIIC tumor cells from tumors treated in vivo than toward bone‐marrow CFU‐GM from the same animals. TNP‐470 had a dose‐modifying effect on the toxicity of cyclophosphamide toward FSaIIC tumor cells which amounted to an 8‐fold increase in tumor‐cell killing at a cyclophosphamide dose of 500 mg/kg. Treatment with TNP‐470 and minocycline increased the permeability of the FSaII fibrosarcoma in vivo to the fluorescent dye Hoechst 33342 and increased the killing of both the bright and the dim tumor cells by cyclophosphamide. TNP‐470, especially in combination with minocycline, formed a highly effective modulator combination for treatment of the Lewis lung carcinoma with cytotoxic cancer therapies against primary and metastatic disease. The combination of TNP‐470/minocycline and cyclophosphamide led to 40 to 50% long‐term survivors in Lewis‐lung‐carcinoma‐bearing animals. Our results indicate that the use of anti‐angiogenic modulators in cancer therapy is a very promising area for further study. © 1994 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of angiogenesis during the transition from hyperplasia to neoplasia
Folkman, J., Watson, K., Ingber, D., & Hanahan, D. (1989) · Nature · doi:10.1038/339058a0 · Cited by 1,879
Cited by
Angiogenesis in cancer, vascular, rheumatoid and other disease
Folkman, J. (1995) · Nature Medicine · doi:10.1038/nm0195-27 · Cited by 7,627
Endostatin: an endogenous inhibitor of angiogenesis and tumor growth
O'Reilly, M. S., Boehm, T., Shing, Y., Fukai, N., Vasios, G., Lane, W. S., Flynn, E., Birkhead, J. R., Olsen, B. R., & Folkman, J. (1997) · Cell · doi:10.1016/s0092-8674(00)81848-6 · Cited by 4,486
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
Clinical translation of angiogenesis inhibitors
Kerbel, R., & Folkman, J. (2002) · Nature Reviews Cancer · doi:10.1038/nrc905 · Cited by 1,517
Angiostatin induces and sustains dormancy of human primary tumors in mice
O'Reilly, M. S., Holmgren, L., Chen, C., & Folkman, J. (1996) · Nature Medicine · doi:10.1038/nm0696-689 · Cited by 1,184
Metadata
- Authors
- Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y., & Brem, H.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 1994-06-15
- Volume
- 57
- Issue
- 6
- Pages
- 920-925
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2140403987
- Cited by
- 231
- References
- 1
- FWCI
- 5.52
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents. https://app.cochat.ai/papers/10.1002/ijc.2910570624
- The paper
- Teicher, B. A., Holden, S. A., Ara, G., Sotomayor, E. A., Huang, Z. D., Chen, Y., & Brem, H. (1994). Potentiation of cytotoxic cancer therapies by TNP‐470 alone and with other anti‐angiogenic agents. International Journal of Cancer. https://doi.org/10.1002/ijc.2910570624
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.